

Evaluating the Role of Cannabidiol in Developmental and Epileptic Encephalopathies: Clinical Rationale and Emerging Evidence

Resource	Address
Castillo-Arellano J, Canseco-Alba A, Cutler SJ, León F. The polypharmacological effects of cannabidiol. <i>Molecules</i> . 2023;28:3271.	https://pmc.ncbi.nlm.nih.gov/articles/PMC10096752/
Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. <i>N Engl J Med</i> . 2017;376:2011-2020.	https://pubmed.ncbi.nlm.nih.gov/28538134/
Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. <i>N Engl J Med</i> . 2018;378:1888-1897.	https://pubmed.ncbi.nlm.nih.gov/29768152/
Gabarin A, Yarmolinsky L, Budovsky A, et al. Cannabis as a source of approved drugs: A new look at an old problem. <i>Molecules</i> . 2023;28:7686.	https://pubmed.ncbi.nlm.nih.gov/38067416/
Ghosh S, Sinha JK, Ghosh S, Sharma H, Bhaskar R, Narayanan KB. A comprehensive review of emerging trends and innovative therapies in epilepsy management. <i>Brain Sci</i> . 2023;13:1305.	https://pubmed.ncbi.nlm.nih.gov/37759906/
Martinez Naya N, Kelly J, Corna G, et al. An overview of cannabidiol as a multifunctional drug: Pharmacokinetics and cellular effects. <i>Molecules</i> . 2024;29:473.	https://pmc.ncbi.nlm.nih.gov/articles/PMC10818442/
Nguyen C, Moeller KE, McGuire M, Melton BL. Consumer perception, knowledge, and uses of cannabidiol. <i>Ment Health Clin</i> . 2023;13:217-224.	https://pmc.ncbi.nlm.nih.gov/articles/PMC10732126/
Odieka AE, Obuzor GU, Oyedeki OO, Gondwe M, Hosu YS, Oyedeki AO. The medicinal natural products of <i>Cannabis sativa</i> : A review. <i>Molecules</i> . 2022;27:1689.	https://pubmed.ncbi.nlm.nih.gov/35268790/
O'Sullivan SE, Jensen SS, Nikolajsen GN, Bruun HZ, Bhuller R, Hoeng J. The therapeutic potential of purified cannabidiol. <i>J Cannabis Res</i> . 2023;5:21.	https://pubmed.ncbi.nlm.nih.gov/37312194/
Patel P, Curry S. Cannabidiol (CBD) in Clinical Care. <i>StatPearls</i> . Last update May 7, 2024.	https://www.ncbi.nlm.nih.gov/sites/books/NBK556048/
Patel AD, Szaflarski JP, Lyons PD, et al. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program. <i>Epilepsia</i> . 2025;66:3730-3740.	https://pubmed.ncbi.nlm.nih.gov/40673944/
Perulli M, Bianchetti M, Pantalone G, et al. Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies. <i>Epilepsia Open</i> . 2025;10:1806-1813.	https://pubmed.ncbi.nlm.nih.gov/41165013/
Pratama R, Muhaimin M, Khairinisa M, Chaerunisaa AY. Adjunctive cannabidiol for drug-resistant epilepsy: A systematic review and meta-analysis of randomized trials across syndromes, formulations, and dose ranges. <i>Ther</i>	https://pubmed.ncbi.nlm.nih.gov/42179430/

<i>Clin Risk Manag.</i> 2026;22:601774.	
Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. <i>Epilepsy Behav.</i> 2022;128:108577.	https://pubmed.ncbi.nlm.nih.gov/35151190/
Sharma P, Holland A, Sheikh T, et al. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. <i>PEC Innov.</i> 2022;1:100044.	https://pmc.ncbi.nlm.nih.gov/articles/PMC10194378/
Sideris A, Doan LV. An overview of cannabidiol. <i>Anesth Analg.</i> 2024;138:54-68.	https://pubmed.ncbi.nlm.nih.gov/38108806/
Singh K, Bhushan B, Chanchal DP, et al. Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: A comprehensive review. <i>Behav Neurol.</i> 2023;2023:8825358.	https://pubmed.ncbi.nlm.nih.gov/37868743/
Swenson K. Beyond the hype: A comprehensive exploration of CBD's biological impacts and mechanisms of action. <i>J Cannabis Res.</i> 2025;7:24.	https://pmc.ncbi.nlm.nih.gov/articles/PMC12067965/
Szaflarski M, McGoldrick P, Currens L, et al. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists. <i>Epilepsy Behav.</i> 2020;109:107102.	https://pubmed.ncbi.nlm.nih.gov/32442891/

Resources and Societies

Resource	Address
American Academy of Neurology™. AAN position: Use of medical cannabis for neurological disorders. 2020.	https://www.aan.com/advocacy/medical-cannabis-position-statement
American Epilepsy Society. Guidelines.	https://aesnet.org/clinical-care/clinical-guidance/guidelines
Epilepsy Alliance America. Support Groups.	https://www.epilepsyallianceamerica.org/programs-services/support-groups/
Epilepsy Foundation. Find Your Local Epilepsy Foundation.	https://www.epilepsy.com/local
Epilepsy Foundation. Individual and Family Services.	https://www.epilepsy.com/programs/family-services
Substance Abuse and Mental Health Services Administration (SAMHSA). Advisory: Cannabidiol (CBD) Potential Harm, Side Effects, and Unknowns	https://www.samhsa.gov/resource/ebp/advisory-cbd-potential-harms-side-effect-unknowns

All URLs accessed October 9, 2026